Conba Group Overview
- Year Founded
-
1969
- Status
-
Public
- Employees
-
7,826
- Stock Symbol
-
600572
- Investments
-
15
- Share Price
-
$0.62
- (As of Wednesday Closing)
Conba Group General Information
Description
Zhejiang Conba Pharmaceutical Co Ltd is engaged in the Pharmaceutical research and development, manufacturing, wholesale and distribution business.
Contact Information
Website
www.conbagroup.comCorporate Office
- Number 568 Binkang Road, Binjiang Science and Technology Economic Park
- Hangzhou High-tech Development Zone
- Hangzhou, Zhejiang 310052
- China
Corporate Office
- Number 568 Binkang Road, Binjiang Science and Technology Economic Park
- Hangzhou High-tech Development Zone
- Hangzhou, Zhejiang 310052
- China
Conba Group Stock Performance
As of 18-Nov-2026, Conba Group’s stock price is $0.62. Its current market cap is $1.58B with 2.54B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.62 | $0.63 | $0.55 - $0.76 | $1.58B | 2.54B | 46.9M | $0.03 |
Conba Group Financials Summary
As of 30-Sep-2026, Conba Group has a trailing 12-month revenue of $991M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,532,371 | 1,567,848 | 1,610,157 | 1,649,939 |
| Revenue | 990,590 | 900,173 | 907,979 | 951,648 |
| EBITDA | 91,643 | 136,308 | 154,685 | 152,007 |
| Net Income | 66,265 | 65,963 | 86,742 | 83,616 |
| Total Assets | 1,561,521 | 1,426,995 | 1,356,389 | 1,585,396 |
| Total Debt | 28,279 | 43,407 | 58,049 | 146,163 |
Conba Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Conba Group Patents
Conba Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023246355-A1 | Ginkgo leaf organic acid extract, method for prearing same and use thereof | Inactive | 21-Jun-2022 | ||
| GB-202112782-D0 | Compound separated from root bark of ginkgo biloba and use thereof | Active | 29-Mar-2019 | ||
| GB-2597145-A | Compound separated from root bark of ginkgo biloba and use thereof | Active | 29-Mar-2019 | ||
| GB-2597145-B | Compound separated from root bark of ginkgo biloba and use thereof | Active | 29-Mar-2019 | ||
| WO-2020199568-A1 | Compound separated from root bark of ginkgo biloba and use thereof | Inactive | 29-Mar-2019 | C07D307/91 |
Conba Group Signals
Conba Group Investments & Acquisitions (15)
Conba Group’s most recent deal was a Later Stage VC with ZhenShiMing. The deal was made on 17-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ZhenShiMing | 17-Apr-2024 | Later Stage VC | Pharmaceuticals | ||
| Zhejiang Zhencheng Pharmaceutical Technology | 23-Mar-2023 | Secondary Transaction - Private | Specialty Retail | ||
| Zhejiang University of Chinese Medicine Pieces | 14-Oct-2022 | Merger/Acquisition | Pharmaceuticals | ||
| Fengdeng Enviroment | 01-Dec-2021 | Later Stage VC | Environmental Services (B2B) | ||
| Xique Pharmaceutical | 14-Apr-2020 | Later Stage VC | Drug Discovery |
Conba Group ESG
Risk Overview
Risk Rating
Updated January, 31, 2024
32.4 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Pharmaceuticals
Subindustry
of 438
Rank
Percentile
Conba Group Exits (4)
Conba Group’s most recent exit was on 23-Mar-2023 from Zhejiang Zhencheng Pharmaceutical Technology. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Zhejiang Zhencheng Pharmaceutical Technology | 23-Mar-2023 | Completed |
|
||
| Xique Pharmaceutical | 14-Apr-2020 | Completed |
|
||
| Zhejiang Zhencheng Pharmaceutical Technology | 08-Jun-2015 | Completed |
|
||
| Forest Packaging | 27-Nov-2013 | Merger/Acquisition | Completed |
Conba Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zhejiang University of Chinese Medicine Pieces | Hangzhou, China | 1989 |
Conba Group FAQs
-
When was Conba Group founded?
Conba Group was founded in 1969.
-
Where is Conba Group headquartered?
Conba Group is headquartered in Hangzhou, China.
-
What is the size of Conba Group?
Conba Group has 7,826 total employees.
-
What industry is Conba Group in?
Conba Group’s primary industry is Pharmaceuticals.
-
Is Conba Group a private or public company?
Conba Group is a Public company.
-
What is Conba Group’s stock symbol?
The ticker symbol for Conba Group is 600572.
-
What is the current stock price of Conba Group?
As of 18-Nov-2026 the stock price of Conba Group is $0.62.
-
What is the current market cap of Conba Group?
The current market capitalization of Conba Group is $1.58B.
-
What is Conba Group’s current revenue?
The trailing twelve month revenue for Conba Group is $991M.
-
What is Conba Group’s annual earnings per share (EPS)?
Conba Group’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process